ONCAlert | Upfront Therapy for mRCC
Videos  >  

Mesa Advises Community Oncologists on JAK Inhibitors for Intermediate-Risk Myelofibrosis

Ruben Mesa, MD
Published Online:7:24 PM, Thu November 21, 2019


Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) in the community setting for patients with intermediate-risk myelofibrosis.

JAK inhibition is an alternative option and as such, it opens the door to improvements in outcomes. Mesa says this has been seen previously when multiple options became available in CML, MDS, and AML. The majority of patients diagnosed with myelofibrosis are already on therapy. Those patients who have a suboptimal response to their current treatment do not have many second-line options outside of clinical trials. Therefore, having an approved agent like ruxolitinib and fedratinib.

When deciding on treatment for newly diagnosed patients in the future, Mesa explains that oncologists should gather subset analysis data to understand how to sequence the available agents for patients with intermediate-risk myelofibrosis.  
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.